DOCSLIB.ORG

上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser. If you have sold or transferred all your shares in Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*, you should at once hand this circular, together with the enclosed form of proxy and reply slip, to the purchaser(s) or transferee(s) or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s). Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular. 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 02196) ANNUAL REPORT 2017 BOARD REPORT 2017 SUPERVISORY COMMITTEE REPORT 2017 FINAL ACCOUNTS REPORT 2017 PROFIT DISTRIBUTION PROPOSAL 2017 RE-APPOINTMENT OF AUDITORS RPT/CT REPORT APPRAISAL RESULTS APPRAISAL PROGRAM ENTRUSTED LOAN/BORROWING QUOTA TOTAL BANK CREDIT APPLICATIONS AUTHORIZATION TO DISPOSE OF LISTED SECURITIES EXTERNAL GUARANTEES GRANT OF GENERAL MANDATE TO ISSUE A SHARES AND/OR H SHARES ELECTION OF NON-EXECUTIVE DIRECTORS AND NOTICE OF AGM A letter from the Board is set out on pages 4 to 11 of this circular. Notice convening the AGM of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to be held at Shanghai Film Art Center, No. 160 Xinhua Road, Shanghai, the PRC on 27 June 2018 (Wednesday) at 1:30 p.m. is set out on pages N-1 to N-5 of this circular. The reply slip and form of proxy for use at the AGM are enclosed herewith and also published on the websites of the Hong Kong Stock Exchange (http://www.hkexnews.hk) and of the Company (http://www.fosunpharma.com). Whether or not you are able to attend the AGM, you are reminded to complete, sign and return the reply slip and the form of proxy enclosed, in accordance with the instructions printed thereon. For holders of H Shares, the reply slip shall be lodged at the Company’s Hong Kong share registrar for H Shares, Tricor Investor Services Limited, at Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong no later than twenty (20) days before the holding of the AGM (i.e. 7 June 2018 (Thursday) by hand, by post or by fax. The form of proxy shall be lodged at the Company’s Hong Kong share registrar for H Shares, Tricor Investor Services Limited, at Level 22, Hopewell Centre, 183 Queen’s Road East, Hong Kong no later than 24 hours before the holding of the AGM. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM should you so wish. * for identification purposes only 9 May 2018 CONTENTS Page Definitions ........................................................ 1 Letter from the Board ............................................... 4 Appendix I – Board Report 2017................................ I-1 Appendix II – Supervisory Committee Report 2017.................. II-1 Appendix III – Final Accounts Report 2017......................... III-1 Appendix IV – RPT/CT Report .................................. IV-1 Appendix V – Appraisal Results ................................. V-1 Appendix VI – Entrusted Loan/Borrowing Quota .................... VI-1 Appendix VII – Total Bank Credit Applications ...................... VII-1 Appendix VIII – Authorization to Dispose of Listed Securities........... VIII-1 Appendix IX – External Guarantees .............................. IX-1 Appendix X – Grant of General Mandate to Issue A Shares and/or H Shares ...................................... X-1 Appendix XI – Election of Non-executive Directors .................. XI-1 Notice of AGM ..................................................... N-1 –i– DEFINITIONS Unless the context otherwise requires, the following expressions in this circular shall have the following meanings: “A Share(s)” domestic share(s) with a nominal value of RMB1.00 each in the share capital of the Company, which is (are) listed on the Shanghai Stock Exchange and traded in RMB “AGM” the annual general meeting of the Company to be held at Shanghai Film Art Center, No. 160 Xinhua Road, Shanghai, the PRC on Wednesday, 27 June 2018 at 1:30 p.m. or any adjournment thereof “Articles of Association” or The articles of association of the Company as effective at “Articles” the time “Associate(s)” has the meaning ascribed to it under the Hong Kong Listing Rules “Board” the board of Directors of the Company “Business Day” any day (excluding Saturday and Sunday) on which banks in Hong Kong are generally open for business “Company Law” the Company Law of the PRC as amended, supplemented or otherwise modified from time to time “Company” or “Fosun Pharma” Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司), a joint stock limited company incorporated in the PRC with limited liability, the H Shares and A Shares of which are listed and traded on the main board of the Hong Kong Stock Exchange and the Shanghai Stock Exchange, respectively “Controlling shareholder(s)” has the meaning ascribed to it under the Hong Kong Listing Rules “CSRC” China Securities Regulatory Commission “Director(s)” the director(s) of the Company “Fosun Finance” Shanghai Fosun Group Finance Corporation Limited* (上海復星高科技集團財務有限公司), a limited liability company incorporated in the PRC, and a connected person of the Company –1– DEFINITIONS “Fosun High Tech” Shanghai Fosun High Technology (Group) Company Limited (上海復星高科技(集團)有限公司), a limited liability company incorporated in the PRC, and a direct wholly-owned subsidiary of Fosun International and the controlling shareholder of the Company “Fosun International” Fosun International Limited, a company incorporated in Hong Kong with limited liability, the shares of which are listed on the main board of the Hong Kong Stock Exchange (stock code: 00656), and the controlling shareholder of the Company “Gland Pharma” Gland Pharma Limited, a limited liability company incorporated in India, and a subsidiary of the Company “General Mandate to Issue the general mandate to allot, issue or otherwise deal with A Shares and/or H Shares” A Shares and/or H Shares of the Company proposed to be granted at the AGM “Group” the Company and its subsidiaries “H Share(s)” overseas listed foreign share(s) with nominal value of RMB1.00 each in the share capital of the Company, which is(are) listed on the Hong Kong Stock Exchange and traded in Hong Kong dollars “H Shareholder(s)” holder(s) of H Shares “HK$” or “HKD” Hong Kong dollars, the lawful currency of Hong Kong “HKFRS” Hong Kong Financial Reporting Standards “Hong Kong” the Hong Kong Special Administrative Region of the PRC “Hong Kong Listing Rules” or The Rules Governing the Listing of Securities on the “Stock Exchange Listing Hong Kong Stock Exchange, as amended from time to Rules” time “Hong Kong Stock Exchange” The Stock Exchange of Hong Kong Limited “Latest Practicable Date” 30 April 2018, being the latest practicable date prior to the printing of this circular of ascertaining certain information herein –2– DEFINITIONS “New Third Board” The National Equities Exchange and Quotations (全國中 小企業股份轉讓系統) “Notice of AGM” the notice of the AGM dated 9 May 2018 set out on pages N-1 to N-5 of this circular “PRC” or “China” the People’s Republic of China (for the purpose of this circular, excluding Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan) “Reporting Period” the 12-month period ended 31 December 2017 “RMB” Renminbi, the lawful currency of the PRC “Securities Law” the Securities Laws of the PRC, as amended, supplemented or otherwise modified from time to time “SFO” Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) “Shanghai Stock Exchange” or the Shanghai Stock Exchange “SSE” “Share(s)” share(s) of the Company, including A Shares and H Shares “Shareholder(s)” holder(s) of Share(s) “Sinopharm” Sinopharm Group Co. Ltd. (國藥控股股份有限公司), a joint stock limited company incorporated in the PRC, the shares of which are listed on the main board of the Hong Kong Stock Exchange (stock code: 01099) “SSE Listing Rules” Rules Governing the Listing of Stocks on Shanghai Stock Exchange, as amended from time to time “Substantial Shareholders” has the meaning ascribed to it under the Hong Kong Listing Rules “Supervisor(s)” the supervisor(s) of the Company “Supervisory Committee” the committee of supervisors of the Company “%” percent –3– LETTER FROM THE BOARD 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 02196) Executive Directors: Registered Office: Mr. Chen Qiyu (Chairman) 9th Floor, No. 510 Caoyang Road Mr. Yao Fang (Co-Chairman) Putuo District Mr. Wu Yifang (President, CEO) Shanghai, 200063, China Non-executive Directors: Headquarter: Mr. Wang Qunbin Building A Mr. Wang Can No. 1289 Yishan Road Shanghai, 200233, China Independent Non-executive Directors: Mr. Cao Huimin Principal Place of Business Mr. Jiang Xian in Hong Kong: Dr. Wong Tin Yau Kelvin Level 54 Mr. Wai Shiu Kwan Danny Hopewell Centre 183 Queen’s Road East Hong Kong 9 May 2018 To the Shareholders Dear Sir or Madam, ANNUAL REPORT 2017 BOARD REPORT 2017 SUPERVISORY COMMITTEE REPORT 2017 FINAL ACCOUNTS REPORT 2017 PROFIT DISTRIBUTION PROPOSAL 2017 RE-APPOINTMENT OF AUDITORS RPT/CT REPORT APPRAISAL RESULTS APPRAISAL PROGRAM ENTRUSTED LOAN/BORROWING QUOTA TOTAL BANK CREDIT APPLICATIONS AUTHORIZATION TO DISPOSE OF LISTED SECURITIES EXTERNAL GUARANTEES GRANT OF GENERAL MANDATE TO ISSUE A SHARES AND/OR H SHARES ELECTION OF NON-EXECUTIVE DIRECTORS AND NOTICE OF AGM –4– LETTER FROM THE BOARD I.
Recommended publications
  • Annual Report

    Annual Report

    2020 (Incorporated in Hong Kong with limited liability) (Stock Code : 00656) Annual Report Profit Attributable to Owners of the Parent RMB 8,017.9 million Innovation & Win The year 2020 might be the most challenging year for Fosun, yet it was also the best year. After the pandemic, we continue with the “wartime mechanism” and maintain the fighting spirit that we have developed during the global combat against COVID-19. This has resulted in our resilient business performance throughout the year. The pandemic has also allowed us to refine further our capabilities of the Company accumulated over the years for “Industry Operations + Industrial Investment”, FC2M model, globalization and technology innovation. Fosun has thus evolved and become even stronger. The theme of Fosun’s annual report this year is “Innovation & Win”. “Innovation” means Fosun always attaches great importance to innovation. We recognize that we can create world-class products only by increasing investment in innovation and R&D. It is also because of our investment in technology innovation in various industries over the years, as well as leveraging on Fosun’s diversified and globalized business portfolio, the development model of “Industry Operations + Industrial Investment”, and the “wartime” mode that it has upkept since the battle against the pandemic, that together effectively defended the impact brought by the external environment and brought the Group a resilient performance, thereby creating mutually beneficial and win-win situation to all stakeholders. The year 2021 is a new starting point for Fosun’s transformation. Facing the huge opportunities in the industrial internet era, we will continue to create good products and put the operation of customers (C-end) as our top priority to fully unlock the multiplier growth of good products and customer resources in Fosun’s ecosystem.
  • Biontech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine

    Biontech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine

    BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine January 25, 2021 COMIRNATY® (also known as BNT162b2, Chinese product name: 復必泰TM) is the first COVID-19 vaccine to receive Authorization for Emergency Use in Hong Kong MAINZ, GERMANY, and SHANGHAI, CHINA, January 25, 2021 —BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of the Hong Kong Special Administrative Region of the PRC (“Hong Kong”), the COVID-19 vaccine COMIRNATY® (also known as BNT162b2, Chinese product name: 復必泰TM) based on BioNTech’s proprietary mRNA technology has received authorization for emergency use in Hong Kong. The vaccine will be produced in BioNTech’s manufacturing facilities in Germany and supplied to Hong Kong for administration under the Hong Kong SAR Government’s COVID-19 Vaccination Program. “We are excited and encouraged that COMIRNATY® has been authorized to emergency use in Hong Kong. This is an important milestone in the joint efforts of BioNTech and Fosun Pharma to achieve vaccine accessibility globally. We will continue working closely with BioNTech to complete the ongoing clinical trial and marketing registration in Greater China,” Wu Yifang, Chairman and CEO of Fosun Pharma said. “We will also cooperate closely with HKSAR regarding vaccination deployment plan to ensure that Hong Kong citizens can receive a well-tolerated and effective mRNA COVID-19 vaccine as soon as possible in order to protect the health of millions of households.” On 16 March 2020, BioNTech and Fosun Pharma announced a strategic collaboration to work jointly on the development and commercialization of a COVID-19 vaccine product in Greater China based on BioNTech’s proprietary mRNA technology platform.
  • 2020 Shanghai Foreign Investment Guide Shanghai Foreign Shanghai Foreign Investment Guide Investment Guide

    2020 Shanghai Foreign Investment Guide Shanghai Foreign Shanghai Foreign Investment Guide Investment Guide

    2020 SHANGHAI FOREIGN INVESTMENT GUIDE SHANGHAI FOREIGN SHANGHAI FOREIGN INVESTMENT GUIDE INVESTMENT GUIDE Contents Investment Chapter II Promotion 61 Highlighted Investment Areas 10 Institutions Preface 01 Overview of Investment Areas A Glimpse at Shanghai's Advantageous Industries Appendix 66 Chapter I A City Abundant in 03 Chapter III Investment Opportunities Districts and Functional 40 Enhancing Urban Capacities Zones for Investment and Core Functions Districts and Investment Influx of Foreign Investments into Highlights the Pioneer of China’s Opening-up Key Functional Zones Further Opening-up Measures in Support of Local Development SHANGHAI FOREIGN SHANGHAI FOREIGN 01 INVESTMENT GUIDE INVESTMENT GUIDE 02 Preface Situated on the east coast of China highest international standards Secondly, the openness of Shanghai Shanghai is becoming one of the most At the beginning of 2020, Shang- SHFTZ with a new area included; near the mouth of the Yangtze River, and best practices. As China’s most translates into a most desired invest- desired investment destinations for hai released the 3.0 version of its operating the SSE STAR Market with Shanghai is internationally known as important gateway to the world, ment destination in the world char- foreign investors. business environment reform plan its pilot registration-based IPO sys- a pioneer of China’s opening to the Shanghai has persistently functioned acterized by increasing vitality and Thirdly, the openness of Shanghai is – the Implementation Plan on Deep- tem; and promoting the integrated world for its inclusiveness, pursuit as a leader in the national opening- optimized business environment. shown in its pursuit of world-lead- ening the All-round Development of a development of the YRD region as of excellence, cultural diversity, and up initiative.
  • STOXX Hong Kong All Shares 50 Last Updated: 01.12.2016

    STOXX Hong Kong All Shares 50 Last Updated: 01.12.2016

    STOXX Hong Kong All Shares 50 Last Updated: 01.12.2016 Rank Rank (PREVIOUS ISIN Sedol RIC Int.Key Company Name Country Currency Component FF Mcap (BEUR) (FINAL) ) KYG875721634 BMMV2K8 0700.HK B01CT3 Tencent Holdings Ltd. CN HKD Y 128.4 1 1 HK0000069689 B4TX8S1 1299.HK HK1013 AIA GROUP HK HKD Y 69.3 2 2 CNE1000002H1 B0LMTQ3 0939.HK CN0010 CHINA CONSTRUCTION BANK CORP H CN HKD Y 60.3 3 4 HK0941009539 6073556 0941.HK 607355 China Mobile Ltd. CN HKD Y 57.5 4 3 CNE1000003G1 B1G1QD8 1398.HK CN0021 ICBC H CN HKD Y 37.7 5 5 CNE1000001Z5 B154564 3988.HK CN0032 BANK OF CHINA 'H' CN HKD Y 32.6 6 7 KYG217651051 BW9P816 0001.HK 619027 CK HUTCHISON HOLDINGS HK HKD Y 32.0 7 6 HK0388045442 6267359 0388.HK 626735 Hong Kong Exchanges & Clearing HK HKD Y 28.5 8 8 CNE1000003X6 B01FLR7 2318.HK CN0076 PING AN INSUR GP CO. OF CN 'H' CN HKD Y 26.5 9 9 CNE1000002L3 6718976 2628.HK CN0043 China Life Insurance Co 'H' CN HKD Y 20.4 10 15 HK0016000132 6859927 0016.HK 685992 Sun Hung Kai Properties Ltd. HK HKD Y 19.4 11 10 HK0883013259 B00G0S5 0883.HK 617994 CNOOC Ltd. CN HKD Y 18.9 12 12 HK0002007356 6097017 0002.HK 619091 CLP Holdings Ltd. HK HKD Y 18.3 13 13 KYG2103F1019 BWX52N2 1113.HK HK50CI CK Property Holdings HK HKD Y 17.9 14 11 CNE1000002Q2 6291819 0386.HK CN0098 China Petroleum & Chemical 'H' CN HKD Y 16.8 15 14 HK0688002218 6192150 0688.HK 619215 China Overseas Land & Investme CN HKD Y 14.8 16 16 HK0823032773 B0PB4M7 0823.HK B0PB4M Link Real Estate Investment Tr HK HKD Y 14.6 17 17 CNE1000003W8 6226576 0857.HK CN0065 PetroChina Co Ltd 'H' CN HKD Y 13.5 18 19 HK0003000038 6436557 0003.HK 643655 Hong Kong & China Gas Co.
  • ACAL China Equity Nov17

    ACAL China Equity Nov17

    ARETE CAPITAL ASIA CHINA: VALUE IN SELECTED NAMES CHINA EQUITY – OVERVIEW CHINA IS TAKING ITS PLACE ON THE WORLD STAGE • China is a critical player in the world economy and is the worlds largest economy on a purchasing power parity basis. • Xi’s position has been reinforced for the next 5yrs and possibly beyond. The new leadership will retain existing key policies with a focus on economic reform and an emphasis on foreign policy. ECONOMIC TRANSFORMATION WELL UNDERWAY • ‘Smokestack’ industries (coal, aluminium and steel) and ‘providing for populace’ businesses (consumer staples and healthcare) are no longer so dominant and being overtaken by manufacturers and service companies. • In many cases, these new ‘service’ industries are redefining business models in established sectors • The China government has selected and carefully encouraged special policies/industries to have Chinese operations challenge the established order – internally and externally INVESTMENT OPPORTUNITIES EXIST • Amongst the many transformations taking place in China, there are numerous great investment opportunities. We do not recommend an index, but selected stocks • Some of these stocks have made significant gains over the last 12months, but there is still more to come 2 CONTENT OVERVIEW ECONOMY Economy Issues Diversification 4 5 6 Equities Remninbi VALUATIONS 7 8 SITUATIONS MiddlePORTFOLIO Class ecosystem ADVISORY 9 10 SELECTED STOCKS Preferred 11 Valuations 13 3 CHINA – ECONOMY CHINA’s ECONOMIC GROWTH REMAINS RESILIENT … • IMF forecasts (not a leading indicator)
  • Hang Seng Indexes Announces Index Review Results

    Hang Seng Indexes Announces Index Review Results

    14 August 2020 Hang Seng Indexes Announces Index Review Results Hang Seng Indexes Company Limited (“Hang Seng Indexes”) today announced the results of its review of the Hang Seng Family of Indexes for the quarter ended 30 June 2020. All changes will take effect on 7 September 2020 (Monday). 1. Hang Seng Index The following constituent changes will be made to the Hang Seng Index. The total number of constituents remains unchanged at 50. Inclusion: Code Company 1810 Xiaomi Corporation - W 2269 WuXi Biologics (Cayman) Inc. 9988 Alibaba Group Holding Ltd. - SW Removal: Code Company 83 Sino Land Co. Ltd. 151 Want Want China Holdings Ltd. 1088 China Shenhua Energy Co. Ltd. - H Shares The list of constituents is provided in Appendix 1. The Hang Seng Index Advisory Committee today reviewed the fast expanding innovation and new economy sectors in the Hong Kong capital market and agreed with the proposal from Hang Seng Indexes to conduct a comprehensive study on the composition of the Hang Seng Index. This holistic review will encompass various aspects including, but not limited to, composition and selection of constituents, number of constituents, weightings, and industry and geographical representation, etc. The underlying aim of the study is to ensure the Hang Seng Index continues to serve as the most representative and important benchmark of the Hong Kong stock market. Hang Seng Indexes will report its findings and propose recommendations to the Advisory Committee within six months. The number of constituents of the Hang Seng Index may increase during this period. Hang Seng Indexes Announces Index Review Results /2 2.
  • Draft Schedule

    Draft Schedule

    2014 Fact-Finding Trip to China – Beijing & Shanghai SUNDAY - FRIDAY, OCT. 26- OCT. 31, 2014 DRAFT SCHEDULE SUNDAY, OCTOBER 26 - BEIJING Grand Hyatt Hotel, Beijing, China 9:00am - IPO- PPAC Conference (open to all attendees) 4:30pm Yuanwanglou Hotel, Beijing 57 Middle Beisanhuan Road, Haidian District, Beijing 北京市海淀区北三环中路57号（北大平桥西北角) 6:30 PM - Welcome Dinner for the IPO Delegation at Grand Hyatt Hotel in the Drawing Room II, LG Level. 9:30 PM Keynote Speaker: Joel Blank, the USPTO attaché, US Embassy Beijing Sponsored by Wan Hui Da Law Firm MONDAY, OCTOBER 27 - BEIJING TBC - Meeting with the State Intellectual Property Office Address: No. 6, Xitucheng Lu, Jimenqiao, Haidian District, Beijing 北京市海淀区蓟门桥西土城路6号 Lunch - Lunch provided by IPO at Bellagio (Taiwanese food) Address: 3rd Floor of Global Blue Shopping Centre, 32 Xizhimen Beidajie, Beijing 西直门北大街32号枫蓝国际购物中心3层 Sponsored by China Pat Intellectual Property Office 1:30pm - Meeting with the State Council-Legislative Affairs Office (SCLAO) 3:00pm No. 33 Pinganlixi Street, Xicheng District, Beijing（北京市西城区平安里西大街33号） Dinner - IPO and PPAC Leadership Dinner at Duck de Chine No.98 Jinbao Street, Dong Cheng District, Beijing 100005, P.R.C 北京市东城区金宝街98号 TUESDAY, OCTOBER 28 - BEIJING TBC - Meeting with Beijing High People’s Court No. 10, Jianguomennan Street, Chaoyang District, Beijing 北京市朝阳区建国门南大街10号 Lunch - Lunch provided by IPO at Lost Heaven Address: 23, Qian Men Dong Da Jie, Beijing 100006 北京市东城区前门东大街23号 Afternoon - Meeting with State Administration of Industry and Commerce (SAIC) Trademark Office Address: No. 1 Chemanan Street, Xicheng District, Beijing 北京市西城区车马南街1号中国商标大厦 Dinner - Dinner at Capital M Address: 3/F, No. 2 Qianmen Pedestrian Street (overlooking Tian'anmen Square) Beijing 100051 China 中国 北京市 前门步行街2号3层 Sponsored by CCPIT Patent & Trademark Law Office WEDNESDAY, OCTOBER 29 – BEIJING/SHANGHAI 9:00am - Meeting with Supreme People’s Court 11:00am No.
  • China Pharmaceuticals China Pharmaceuticals Spring Is in the Air – We Expect a Year of Healthy Growth

    China Pharmaceuticals China Pharmaceuticals Spring Is in the Air – We Expect a Year of Healthy Growth

    EQUITIES HEALTHCARE March 2017 By: Zhijie Zhao https://www.research.hsbc.com China Pharmaceuticals China China Pharmaceuticals Spring is in the air – we expect a year of healthy growth The policy pain of 2016 starts to ease and the industry’s fundamentals remain robust Multinational companies are reducing their focus on off-patent drugs in China, opening up a range Equities // Healthcare // Equities of opportunities We raise our target prices between 11% and 25%; we prefer Hengrui, Sino Biopharm and CMS, all rated Buy March 2017 March Disclaimer & Disclosures: This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it EQUITIES ● HEALTHCARE March 2017 THIS CONTENT MAY NOT BE DISTRIBUTED TO THE PEOPLE'S REPUBLIC OF CHINA (THE "PRC") (EXCLUDING SPECIAL ADMINISTRATIVE REGIONS OF HONG KONG AND MACAO) The dark clouds are lifting The pain is easing as the risks associated with industry reforms recede We forecast that the net profit growth of our covered companies will average 19% in 2017e and 23% in 2018e, up from 18% in 2016e We raise our target prices by 11-25%; we prefer Hengrui, Sino Biopharm and CMS, all rated Buy Last year we wrote that China’s attempts to improve the healthcare system were proving painful for pharma companies (China Pharmaceuticals – 2016: Painful symptoms, possible remedies, 1 March 2016). We said that, although efforts to cut the cost of healthcare and improve industry standards would make the first half of 2016 difficult, we remained strong believers in China’s pharma story.
  • COVID-19: China Medical Supply Chains and Broader Trade Issues

    COVID-19: China Medical Supply Chains and Broader Trade Issues

    COVID-19: China Medical Supply Chains and Broader Trade Issues Updated December 23, 2020 Congressional Research Service https://crsreports.congress.gov R46304 SUMMARY R46304 COVID-19: China Medical Supply Chains and December 23, 2020 Broader Trade Issues Karen M. Sutter, The outbreak of Coronavirus Disease 2019 (COVID-19), first in China, and then Coordinator globally, including in the United States, has drawn attention to the ways in which the Specialist in Asian Trade U.S. economy depends on manufacturing and supply chains based in China. This report and Finance aims to assess current developments and identify immediate and longer range China trade issues for Congress. Andres B. Schwarzenberg Analyst in International An area of particular concern to Congress has been U.S. shortages in medical supplies— Trade and Finance including personal protective equipment (PPE) and pharmaceuticals—as the United States stepped up efforts to contain the COVID-19 pandemic with limited domestic Michael D. Sutherland stockpiles and insufficient U.S. industrial capacity. Because of China’s role as a global Analyst in International supplier of PPE, medical devices, antibiotics, and active pharmaceutical ingredients, Trade and Finance reduced exports from China led to shortages of critical medical supplies in the United States. Exacerbating the situation, in early February 2020, the Chinese government nationalized control of the production and distribution of medical supplies in China— directing all production for domestic use—and directed the bureaucracy and Chinese industry to secure supplies from the global market. Once past the initial peak of its COVID-19 outbreak, the Chinese government appears to have prioritized certain countries and selectively released some medical supplies for overseas delivery.
  • 股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co

    股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co

    THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser. If you have sold or transferred all your shares in Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser(s) or transferee(s) or to the bank, stockbroker or other agents through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s). Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular. 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 02196) REPORT ON THE USE OF PROCEEDS PREVIOUSLY RAISED AND NOTICE OF EGM A letter from the Board is set out on pages 3 to 5 of this circular. The notice convening the EGM of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* to be held at 1:30 p.m. on Wednesday, 14 July 2021 at Shanghai Film Art Center, No.
  • Annual Report 2020 03 Corporate Information

    Annual Report 2020 03 Corporate Information

    Our Vision Dedicate to become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market. Our Mission Better health for families worldwide. 02 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Contents 04 Corporate Information 07 Financial Highlights 08 Chairman’s Statement 12 Management Discussion and Analysis 67 Five-Year Statistics 68 Report of the Directors 91 Supervisory Committee Report 93 Corporate Governance Report 104 Environmental, Social and Governance Report 135 Biographical Details of Directors, Supervisors and Senior Management 144 Independent Auditor’s Report 149 Consolidated Statement of Profit or Loss 150 Consolidated Income Statement 151 Consolidated Statement of Financial Position 153 Consolidated Statement of Changes in Equity 155 Consolidated Statement of Cash Flows 157 Notes to Financial Statements 276 Definitions Annual Report 2020 03 Corporate Information Directors Authorized Representatives Executive Director Mr. Wu Yifang (吳以芳)11 Mr. Wu Yifang (吳以芳) Ms. Kam Mei Ha Wendy (甘美霞) (Chairman1 and Chief Executive Officer) Mr. Chen Qiyu (陳啟宇)12 Non-executive Directors Strategic Committee Mr. Chen Qiyu (陳啟宇)2 Mr. Chen Qiyu (陳啟宇) (Chairman) Mr. Yao Fang (姚方)3 Mr. Wu Yifang (吳以芳) Mr. Xu Xiaoliang (徐曉亮) Mr. Yao Fang (姚方) Mr. Gong Ping (龔平)4 Mr. Xu Xiaoliang (徐曉亮) Mr. Pan Donghui (潘東輝)4 Ms. Li Ling (李玲) Mr. Zhang Houlin (張厚林)5 Mr. Liang Jianfeng (梁劍峰)6 Audit Committee Mr. Wang Can (王燦)7 Ms. Mu Haining (沐海寧)9 Mr. Tang Guliang (湯谷良) (Chairman) Mr. Jiang Xian (江憲) Independent Non-executive Directors Mr. Gong Ping (龔平)4 Mr. Jiang Xian (江憲) Mr. Wang Can (王燦)7 Dr. Wong Tin Yau Kelvin (黃天祐) Ms.
  • 2020 NN Development Zone Directory4

    2020 NN Development Zone Directory4

    Development Zone Directory Shanghai, Jiangsu, Zhejiang 2020 Contents Introduction 4 Shanghai 6 Jiangsu 11 Zhejiang 22 Others 32 Imprint Address Publisher: SwissCham China SwissCham Shanghai Administrator: SwissCham Shanghai Carlton Building, 11th Floor, Room1138, 21 Project execution, editorial and Huanghe Road, Shanghai, 200003. P. R. translations: Nini Qi (lead), China Eric Ma 中国上海市黄河路21号鸿祥大厦1138室 邮编 Project direction: Peter Bachmann ：200003 Tel: 021 5368 1248 Copyright 2020 SwissCham China Web: https://www.swisscham.org/shanghai/ 2 Development Zone Directory 2020 Dear Readers, A lot has changed since we published our first edition of the Development Zone Directory back in 2017. But China remains one of the top investment hotspots in the world, despite ongoing trade and other disputes the country faces. While it is true that companies and countries are relocating or building up additional supply chains to lessen their dependence on China, it is also a fact that no other country has the industrial capacity, growing middle class and growth potential. The Chinese market attracts the most foreign direct investment and it well may do so for many years to come, given the large untapped markets in the central and western part of the country. Earlier this year, Premier Li Keqiang mentioned that there are 600 million Chinese citizens living with RMB 1,000 of monthly disposable income. While this may sounds surprising, it also shows the potential that Chinese inner regions have for the future. Investing in China and selling to the Chinese consumers is something that makes sense for companies from around the world. The development zones listed in this directory are here to support and help foreign investors to deal with the unique challenges in the Chinese market.